Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Wilms Tumor × Epirubicin × 1 year × Clear all

Sponsor

Conditions

Breast Neoplasms 15 Triple Negative Breast Neoplasms 10 Lymphoma, Large B-Cell, Diffuse 2 Resectable HER2-positive Breast Cancer 1 Pathologic Complete Response 1 Non-Muscle Invasive Bladder Neoplasms 1 Nasopharyngeal Carcinoma 1 Lymphoma, T-Cell, Peripheral 1 Inflammatory Breast Neoplasms 1 HR+/HER2- Breast Cancer 1 Epstein-Barr Virus Infections 1 Congenital Abnormalities 1 Carcinoma, Adenoid Cystic 1 CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction 1

Interventions

X-Rays 7 Phantoms, Imaging 7 Specimen Handling 6 Magnetic Resonance Spectroscopy 6 Nuclear Medicine Department, Hospital 5 Biopsy 5 fludarabine 3 Vincristine 3 Cyclophosphamide 3 ulixertinib 2 tipifarnib 2 selpercatinib 2 larotrectinib 2 ivosidenib 2 fludarabine phosphate 2 erdafitinib 2 ensartinib 2 Temozolomide 2 Radiotherapy 2 Radiation 2 Irinotecan 2 Etoposide 2 Doxorubicin 2 tazemetostat 1 talazoparib 1 selinexor 1 sargramostim 1 pembrolizumab 1 palbociclib 1 omburtamab I-131 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡